
AstraZeneca PLC
AstraZeneca
AstraZeneca PLC reinforced its status as the most glocalized of the pharmaceutical super-majors in FY2025, generating $58.7 billion in revenue (+8% at constant exchange rates) powered by simultaneous strength in oncology, CVRM, and rare disease portfolios. The company's 2025 performance was marked by extraordinary pipeline productivity: 16 positive Phase III readouts and 43 major regulatory approvals across global jurisdictions. AstraZeneca's China strategy has evolved beyond market access into deep industrial integration—a $15 billion commitment through 2030 aims to transform its Chinese operations into a global hub for cell therapy and radioconjugate manufacturing. The $1.2 billion upfront licensing deal (potential $18.5 billion total) for CSPC's preclinical GLP-1/GIP dual-agonist catapulted AstraZeneca into the metabolic disease arena. With 31 manufacturing sites across 16 countries, an independently operable dual-source supply system isolating Chinese and Western supply chains, and 80,000 employees (20,000+ in China alone), AstraZeneca has constructed a geopolitical risk-hedged operating model that competitors admire but struggle to replicate.
Strengths: The China dual-supply-chain strategy—maintaining completely independent, self-sufficient manufacturing and distribution networks in China and the West—represents the most sophisticated geopolitical risk management framework in the industry, insulating AstraZeneca from US-China decoupling scenarios that threaten competitors' single-source dependencies. Pipeline breadth across oncology (Tagrisso, Imfinzi, Enhertu partnership), CVRM (Farxiga), respiratory, rare disease, and now metabolic disease provides therapeutic diversification matched only by Roche and J&J. The 2025 productivity surge (16 positive Phase IIIs, 43 approvals) demonstrates clinical development execution at peak efficiency.
Weaknesses: The 2023-2024 China senior executive importation and data compliance scandal—though settled—left reputational scarring and elevated compliance oversight costs that continue to weigh on China operational agility. The CSPC obesity drug deal, while strategically necessary, came at an extraordinarily rich price for a Phase I asset, creating substantial binary risk. AstraZeneca's late entry into the GLP-1 metabolic market means competing against Lilly and Novo Nordisk's deeply entrenched physician prescribing habits and patient brand loyalty.Read MoreShow Less
Strengths: The China dual-supply-chain strategy—maintaining completely independent, self-sufficient manufacturing and distribution networks in China and the West—represents the most sophisticated geopolitical risk management framework in the industry, insulating AstraZeneca from US-China decoupling scenarios that threaten competitors' single-source dependencies. Pipeline breadth across oncology (Tagrisso, Imfinzi, Enhertu partnership), CVRM (Farxiga), respiratory, rare disease, and now metabolic disease provides therapeutic diversification matched only by Roche and J&J. The 2025 productivity surge (16 positive Phase IIIs, 43 approvals) demonstrates clinical development execution at peak efficiency.
Weaknesses: The 2023-2024 China senior executive importation and data compliance scandal—though settled—left reputational scarring and elevated compliance oversight costs that continue to weigh on China operational agility. The CSPC obesity drug deal, while strategically necessary, came at an extraordinarily rich price for a Phase I asset, creating substantial binary risk. AstraZeneca's late entry into the GLP-1 metabolic market means competing against Lilly and Novo Nordisk's deeply entrenched physician prescribing habits and patient brand loyalty.
Listed market data
AZN · NYSE · weeklyHistory →- Market cap
- $287 B
- Share price
- USD 175.34
- 1Y change
- +14.0%
- Recent change
- -1.9%
- Since first close
- ×17.4
- Revenue (TTM)
- $61.4 B
11-19
from 1993
Financial history
Full market history- 2026-11USD 175.41$287 B+6.0%
- 2026-10USD 165.41$257 B+2.4%
- 2026-09USD 161.47$264 B-0.4%
- 2026-08USD 162.13$265 B-4.4%
- 2026-07USD 169.64$278 B-10.5%
- 2026-06USD 189.62$310 B+2.1%
- 2026-05USD 185.67$304 B-0.9%
- 2026-04USD 187.37$307 B-5.0%
- 2026-03USD 197.22$323 B-5.4%
- 2026-02USD 208.45$341 B+12.3%
- 2026-01USD 185.54$304 B+0.9%
- 2025-12USD 183.86$301 B—
Ownership & Control
Shareholding as of 2026-06-30- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- 0.05%
- Institutions
- 76.35%(2,509 holders)
- Free float
- 76.39%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines12- AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study - Benzingawww.benzinga.com2026-10-20
- AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple? - Yahoo Financefinance.yahoo.com2026-10-20
- AstraZeneca partners with Oracle for AI-driven clinical trials - Reuterswww.reuters.com2026-10-20
- AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuterswww.reuters.com2026-10-20
- AstraZeneca and Oracle AI Trial Pact: Can the Partnership Reset the Market’s Pricing? - NAI500nai500.com2026-10-20
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $58.7 B | $10.2 B |
| 2024 | $54.1 B | $7 B |
| 2023 | $45.8 B | $6 B |
| 2022 | $44.4 B | $3.3 B |
| 2021 | $37.4 B | $112 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Annual and interim reports published by the exchange or regulator. Links open the official source — files are not hosted on VerityRank.
| Year | Filing | Filed | Source | |
|---|---|---|---|---|
| 2026 | 6-K | 2026-11-16 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-11-16 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-11-16 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-11-16 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-11-02 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-11-02 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-10-30 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-10-27 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-10-22 | SEC EDGAR | Open ↗ |
| 2026 | 6-K | 2026-10-05 | SEC EDGAR | Open ↗ |
Links point to the issuer’s official disclosure platform. We store no filings.
Quick Facts
Headquarters
Founded
Employees
Revenue
Market cap
Factories
Presence
Listing
LSE/NYSE/STO: AZNCategories
Related
Similar listed companies
- Eli Lilly and Company· $1.3 T
- Johnson & Johnson (J&J)· $653 B
- ASML Holding N.V.· $598 B
- Allergan Aesthetics· $508 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $381 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website LSE/NYSE/STO: AZN , AstraZeneca FY & Q4 2025 Results
AstraZeneca $15B China Commitment
AZ-CSPC Obesity Deal ($1.2B Upfront)
